U.S. Physical Therapy, Inc.
U.S. Physical Therapy, Inc. (USPH) Stock Competitors & Peer Comparison
See (USPH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| USPH | $75.64 | +0.41% | 1.2B | 34.74 | $2.18 | +2.33% |
| HCA | $344.50 | +1.16% | 82.9B | 14.47 | $23.80 | +0.80% |
| FMS | $26.15 | +1.24% | 15.3B | 21.08 | $1.24 | +3.02% |
| THC | $156.06 | -0.29% | 14.5B | 9.81 | $15.91 | N/A |
| SOLV | $73.55 | -0.30% | 12.7B | 33.90 | $2.17 | N/A |
| DVA | $145.98 | +0.46% | 11B | 14.49 | $10.07 | N/A |
| EHC | $108.26 | +1.02% | 10.9B | 22.28 | $4.86 | +0.63% |
| UHS | $162.82 | +5.08% | 10.5B | 9.15 | $17.80 | +0.49% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| ENSG | $151.01 | +2.19% | 8.7B | 27.31 | $5.53 | +0.16% |
Stock Comparison
USPH vs HCA Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, HCA has a market cap of 82.9B. Regarding current trading prices, USPH is priced at $75.64, while HCA trades at $344.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas HCA's P/E ratio is 14.47. In terms of profitability, USPH's ROE is +0.06%, compared to HCA's ROE of -2.11%. Regarding short-term risk, USPH is less volatile compared to HCA. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check HCA's competition here
USPH vs FMS Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, FMS has a market cap of 15.3B. Regarding current trading prices, USPH is priced at $75.64, while FMS trades at $26.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas FMS's P/E ratio is 21.08. In terms of profitability, USPH's ROE is +0.06%, compared to FMS's ROE of +0.04%. Regarding short-term risk, USPH is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check FMS's competition here
USPH vs THC Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, THC has a market cap of 14.5B. Regarding current trading prices, USPH is priced at $75.64, while THC trades at $156.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas THC's P/E ratio is 9.81. In terms of profitability, USPH's ROE is +0.06%, compared to THC's ROE of +0.37%. Regarding short-term risk, USPH is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check THC's competition here
USPH vs SOLV Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, SOLV has a market cap of 12.7B. Regarding current trading prices, USPH is priced at $75.64, while SOLV trades at $73.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas SOLV's P/E ratio is 33.90. In terms of profitability, USPH's ROE is +0.06%, compared to SOLV's ROE of +0.12%. Regarding short-term risk, USPH is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check SOLV's competition here
USPH vs DVA Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, DVA has a market cap of 11B. Regarding current trading prices, USPH is priced at $75.64, while DVA trades at $145.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas DVA's P/E ratio is 14.49. In terms of profitability, USPH's ROE is +0.06%, compared to DVA's ROE of +3.94%. Regarding short-term risk, USPH is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check DVA's competition here
USPH vs EHC Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, EHC has a market cap of 10.9B. Regarding current trading prices, USPH is priced at $75.64, while EHC trades at $108.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas EHC's P/E ratio is 22.28. In terms of profitability, USPH's ROE is +0.06%, compared to EHC's ROE of +0.25%. Regarding short-term risk, USPH is less volatile compared to EHC. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check EHC's competition here
USPH vs UHS Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, UHS has a market cap of 10.5B. Regarding current trading prices, USPH is priced at $75.64, while UHS trades at $162.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas UHS's P/E ratio is 9.15. In terms of profitability, USPH's ROE is +0.06%, compared to UHS's ROE of +0.19%. Regarding short-term risk, USPH is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check UHS's competition here
USPH vs OSH Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, USPH is priced at $75.64, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas OSH's P/E ratio is -17.65. In terms of profitability, USPH's ROE is +0.06%, compared to OSH's ROE of +4.64%. Regarding short-term risk, USPH is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check OSH's competition here
USPH vs ENSG Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, ENSG has a market cap of 8.7B. Regarding current trading prices, USPH is priced at $75.64, while ENSG trades at $151.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas ENSG's P/E ratio is 27.31. In terms of profitability, USPH's ROE is +0.06%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, USPH is less volatile compared to ENSG. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ENSG's competition here
USPH vs CHE Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, CHE has a market cap of 6.8B. Regarding current trading prices, USPH is priced at $75.64, while CHE trades at $464.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas CHE's P/E ratio is 22.73. In terms of profitability, USPH's ROE is +0.06%, compared to CHE's ROE of +0.26%. Regarding short-term risk, USPH is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check CHE's competition here
USPH vs LHCG Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, USPH is priced at $75.64, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas LHCG's P/E ratio is 82.83. In terms of profitability, USPH's ROE is +0.06%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, USPH is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check LHCG's competition here
USPH vs OPCH Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, OPCH has a market cap of 4.9B. Regarding current trading prices, USPH is priced at $75.64, while OPCH trades at $30.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas OPCH's P/E ratio is 24.10. In terms of profitability, USPH's ROE is +0.06%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, USPH is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check OPCH's competition here
USPH vs AMED Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, AMED has a market cap of 3.2B. Regarding current trading prices, USPH is priced at $75.64, while AMED trades at $97.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas AMED's P/E ratio is 35.99. In terms of profitability, USPH's ROE is +0.06%, compared to AMED's ROE of +0.10%. Regarding short-term risk, USPH is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check AMED's competition here
USPH vs SGRY Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, SGRY has a market cap of 2.9B. Regarding current trading prices, USPH is priced at $75.64, while SGRY trades at $22.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas SGRY's P/E ratio is -14.59. In terms of profitability, USPH's ROE is +0.06%, compared to SGRY's ROE of -0.10%. Regarding short-term risk, USPH is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check SGRY's competition here
USPH vs ACHC Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, ACHC has a market cap of 2.1B. Regarding current trading prices, USPH is priced at $75.64, while ACHC trades at $22.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas ACHC's P/E ratio is 10.70. In terms of profitability, USPH's ROE is +0.06%, compared to ACHC's ROE of +0.06%. Regarding short-term risk, USPH is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ACHC's competition here
USPH vs ADUS Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, ADUS has a market cap of 2B. Regarding current trading prices, USPH is priced at $75.64, while ADUS trades at $107.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas ADUS's P/E ratio is 24.46. In terms of profitability, USPH's ROE is +0.06%, compared to ADUS's ROE of +0.08%. Regarding short-term risk, USPH is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ADUS's competition here
USPH vs SEM Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, SEM has a market cap of 1.8B. Regarding current trading prices, USPH is priced at $75.64, while SEM trades at $14.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas SEM's P/E ratio is 22.98. In terms of profitability, USPH's ROE is +0.06%, compared to SEM's ROE of +0.10%. Regarding short-term risk, USPH is less volatile compared to SEM. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check SEM's competition here
USPH vs AMEH Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, USPH is priced at $75.64, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas AMEH's P/E ratio is 39.25. In terms of profitability, USPH's ROE is +0.06%, compared to AMEH's ROE of +0.07%. Regarding short-term risk, USPH is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AMEH's competition here
USPH vs BKD Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, BKD has a market cap of 1.8B. Regarding current trading prices, USPH is priced at $75.64, while BKD trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas BKD's P/E ratio is -7.39. In terms of profitability, USPH's ROE is +0.06%, compared to BKD's ROE of -0.96%. Regarding short-term risk, USPH is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check BKD's competition here
USPH vs LFST Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, LFST has a market cap of 1.6B. Regarding current trading prices, USPH is priced at $75.64, while LFST trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas LFST's P/E ratio is -45.89. In terms of profitability, USPH's ROE is +0.06%, compared to LFST's ROE of -0.02%. Regarding short-term risk, USPH is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check LFST's competition here
USPH vs ARDT Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, ARDT has a market cap of 1.5B. Regarding current trading prices, USPH is priced at $75.64, while ARDT trades at $10.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas ARDT's P/E ratio is 6.38. In terms of profitability, USPH's ROE is +0.06%, compared to ARDT's ROE of +0.24%. Regarding short-term risk, USPH is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ARDT's competition here
USPH vs NHC Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, NHC has a market cap of 1.5B. Regarding current trading prices, USPH is priced at $75.64, while NHC trades at $96.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas NHC's P/E ratio is 14.00. In terms of profitability, USPH's ROE is +0.06%, compared to NHC's ROE of +0.11%. Regarding short-term risk, USPH is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check NHC's competition here
USPH vs BKDT Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, USPH is priced at $75.64, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas BKDT's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.06%, compared to BKDT's ROE of -0.96%. Regarding short-term risk, USPH is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check BKDT's competition here
USPH vs ASTH Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, ASTH has a market cap of 1.2B. Regarding current trading prices, USPH is priced at $75.64, while ASTH trades at $23.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas ASTH's P/E ratio is 31.66. In terms of profitability, USPH's ROE is +0.06%, compared to ASTH's ROE of +0.07%. Regarding short-term risk, USPH is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ASTH's competition here
USPH vs MD Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, MD has a market cap of 1.1B. Regarding current trading prices, USPH is priced at $75.64, while MD trades at $12.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas MD's P/E ratio is -12.66. In terms of profitability, USPH's ROE is +0.06%, compared to MD's ROE of -0.11%. Regarding short-term risk, USPH is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check MD's competition here
USPH vs HCSG Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, HCSG has a market cap of 967.6M. Regarding current trading prices, USPH is priced at $75.64, while HCSG trades at $13.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas HCSG's P/E ratio is 94.79. In terms of profitability, USPH's ROE is +0.06%, compared to HCSG's ROE of +0.02%. Regarding short-term risk, USPH is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check HCSG's competition here
USPH vs AGL Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, AGL has a market cap of 796.9M. Regarding current trading prices, USPH is priced at $75.64, while AGL trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas AGL's P/E ratio is -3.21. In terms of profitability, USPH's ROE is +0.06%, compared to AGL's ROE of -0.44%. Regarding short-term risk, USPH is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AGL's competition here
USPH vs PNTG Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, PNTG has a market cap of 792.1M. Regarding current trading prices, USPH is priced at $75.64, while PNTG trades at $22.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas PNTG's P/E ratio is 30.64. In terms of profitability, USPH's ROE is +0.06%, compared to PNTG's ROE of +0.11%. Regarding short-term risk, USPH is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check PNTG's competition here
USPH vs AVAH Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, AVAH has a market cap of 784.3M. Regarding current trading prices, USPH is priced at $75.64, while AVAH trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas AVAH's P/E ratio is 134.00. In terms of profitability, USPH's ROE is +0.06%, compared to AVAH's ROE of -0.12%. Regarding short-term risk, USPH is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AVAH's competition here
USPH vs AMN Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, AMN has a market cap of 740.2M. Regarding current trading prices, USPH is priced at $75.64, while AMN trades at $19.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas AMN's P/E ratio is -4.47. In terms of profitability, USPH's ROE is +0.06%, compared to AMN's ROE of -0.21%. Regarding short-term risk, USPH is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AMN's competition here
USPH vs INNV Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, INNV has a market cap of 488.7M. Regarding current trading prices, USPH is priced at $75.64, while INNV trades at $3.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas INNV's P/E ratio is -15.08. In terms of profitability, USPH's ROE is +0.06%, compared to INNV's ROE of -0.12%. Regarding short-term risk, USPH is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check INNV's competition here
USPH vs SNDA Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, SNDA has a market cap of 468.1M. Regarding current trading prices, USPH is priced at $75.64, while SNDA trades at $24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas SNDA's P/E ratio is -6.74. In terms of profitability, USPH's ROE is +0.06%, compared to SNDA's ROE of -0.53%. Regarding short-term risk, USPH is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check SNDA's competition here
USPH vs AUNA Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, AUNA has a market cap of 453.7M. Regarding current trading prices, USPH is priced at $75.64, while AUNA trades at $6.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas AUNA's P/E ratio is 9.29. In terms of profitability, USPH's ROE is +0.06%, compared to AUNA's ROE of +0.11%. Regarding short-term risk, USPH is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AUNA's competition here
USPH vs CCRN Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, CCRN has a market cap of 452.4M. Regarding current trading prices, USPH is priced at $75.64, while CCRN trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas CCRN's P/E ratio is -25.56. In terms of profitability, USPH's ROE is +0.06%, compared to CCRN's ROE of -0.04%. Regarding short-term risk, USPH is less volatile compared to CCRN. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CCRN's competition here
USPH vs TALKW Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, TALKW has a market cap of 433M. Regarding current trading prices, USPH is priced at $75.64, while TALKW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas TALKW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.06%, compared to TALKW's ROE of -0.04%. Regarding short-term risk, USPH is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check TALKW's competition here
USPH vs TALK Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, TALK has a market cap of 420M. Regarding current trading prices, USPH is priced at $75.64, while TALK trades at $2.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas TALK's P/E ratio is 125.50. In terms of profitability, USPH's ROE is +0.06%, compared to TALK's ROE of -0.04%. Regarding short-term risk, USPH is less volatile compared to TALK. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check TALK's competition here
USPH vs CMPS Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, CMPS has a market cap of 397.4M. Regarding current trading prices, USPH is priced at $75.64, while CMPS trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas CMPS's P/E ratio is -2.15. In terms of profitability, USPH's ROE is +0.06%, compared to CMPS's ROE of -0.72%. Regarding short-term risk, USPH is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CMPS's competition here
USPH vs AIRS Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, AIRS has a market cap of 386.7M. Regarding current trading prices, USPH is priced at $75.64, while AIRS trades at $6.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas AIRS's P/E ratio is -21.36. In terms of profitability, USPH's ROE is +0.06%, compared to AIRS's ROE of -0.21%. Regarding short-term risk, USPH is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AIRS's competition here
USPH vs TOIIW Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, TOIIW has a market cap of 383.7M. Regarding current trading prices, USPH is priced at $75.64, while TOIIW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas TOIIW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.06%, compared to TOIIW's ROE of -4.83%. Regarding short-term risk, USPH is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check TOIIW's competition here
USPH vs CYH Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, CYH has a market cap of 343.3M. Regarding current trading prices, USPH is priced at $75.64, while CYH trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas CYH's P/E ratio is -1.67. In terms of profitability, USPH's ROE is +0.06%, compared to CYH's ROE of +0.11%. Regarding short-term risk, USPH is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CYH's competition here
USPH vs EHAB Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, EHAB has a market cap of 337.2M. Regarding current trading prices, USPH is priced at $75.64, while EHAB trades at $6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas EHAB's P/E ratio is -2.40. In terms of profitability, USPH's ROE is +0.06%, compared to EHAB's ROE of -0.31%. Regarding short-term risk, USPH is less volatile compared to EHAB. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check EHAB's competition here
USPH vs TOI Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, TOI has a market cap of 332.7M. Regarding current trading prices, USPH is priced at $75.64, while TOI trades at $3.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas TOI's P/E ratio is -5.17. In terms of profitability, USPH's ROE is +0.06%, compared to TOI's ROE of -4.83%. Regarding short-term risk, USPH is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check TOI's competition here
USPH vs AONC Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, AONC has a market cap of 291.7M. Regarding current trading prices, USPH is priced at $75.64, while AONC trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas AONC's P/E ratio is -11.49. In terms of profitability, USPH's ROE is +0.06%, compared to AONC's ROE of +0.25%. Regarding short-term risk, USPH is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check AONC's competition here
USPH vs CSU Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, USPH is priced at $75.64, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas CSU's P/E ratio is 0.67. In terms of profitability, USPH's ROE is +0.06%, compared to CSU's ROE of +2.23%. Regarding short-term risk, USPH is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CSU's competition here
USPH vs JYNT Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, JYNT has a market cap of 179M. Regarding current trading prices, USPH is priced at $75.64, while JYNT trades at $11.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas JYNT's P/E ratio is -117.00. In terms of profitability, USPH's ROE is +0.06%, compared to JYNT's ROE of -0.43%. Regarding short-term risk, USPH is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check JYNT's competition here
USPH vs BTMD Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, BTMD has a market cap of 174.2M. Regarding current trading prices, USPH is priced at $75.64, while BTMD trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas BTMD's P/E ratio is 7.71. In terms of profitability, USPH's ROE is +0.06%, compared to BTMD's ROE of -0.19%. Regarding short-term risk, USPH is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check BTMD's competition here
USPH vs DCGO Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, DCGO has a market cap of 140.7M. Regarding current trading prices, USPH is priced at $75.64, while DCGO trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas DCGO's P/E ratio is -142.00. In terms of profitability, USPH's ROE is +0.06%, compared to DCGO's ROE of -0.00%. Regarding short-term risk, USPH is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check DCGO's competition here
USPH vs FVE Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, USPH is priced at $75.64, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas FVE's P/E ratio is -5.64. In terms of profitability, USPH's ROE is +0.06%, compared to FVE's ROE of -0.15%. Regarding short-term risk, USPH is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check FVE's competition here
USPH vs KDLYW Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, USPH is priced at $75.64, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas KDLYW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.06%, compared to KDLYW's ROE of -1.46%. Regarding short-term risk, USPH is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check KDLYW's competition here
USPH vs ALR Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, USPH is priced at $75.64, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas ALR's P/E ratio is -1.11. In terms of profitability, USPH's ROE is +0.06%, compared to ALR's ROE of -0.15%. Regarding short-term risk, USPH is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check ALR's competition here
USPH vs MODV Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, MODV has a market cap of 43.3M. Regarding current trading prices, USPH is priced at $75.64, while MODV trades at $3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas MODV's P/E ratio is -0.19. In terms of profitability, USPH's ROE is +0.06%, compared to MODV's ROE of +6.87%. Regarding short-term risk, USPH is less volatile compared to MODV. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check MODV's competition here
USPH vs CCEL Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, CCEL has a market cap of 40M. Regarding current trading prices, USPH is priced at $75.64, while CCEL trades at $4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas CCEL's P/E ratio is -248.28. In terms of profitability, USPH's ROE is +0.06%, compared to CCEL's ROE of +0.01%. Regarding short-term risk, USPH is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CCEL's competition here
USPH vs IMAC Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, USPH is priced at $75.64, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas IMAC's P/E ratio is -2.27. In terms of profitability, USPH's ROE is +0.06%, compared to IMAC's ROE of -0.78%. Regarding short-term risk, USPH is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check IMAC's competition here
USPH vs PIII Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, PIII has a market cap of 19M. Regarding current trading prices, USPH is priced at $75.64, while PIII trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas PIII's P/E ratio is -0.11. In terms of profitability, USPH's ROE is +0.06%, compared to PIII's ROE of -1.29%. Regarding short-term risk, USPH is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check PIII's competition here
USPH vs AMS Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, AMS has a market cap of 17.1M. Regarding current trading prices, USPH is priced at $75.64, while AMS trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas AMS's P/E ratio is 12.62. In terms of profitability, USPH's ROE is +0.06%, compared to AMS's ROE of +0.06%. Regarding short-term risk, USPH is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AMS's competition here
USPH vs AIH Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, USPH is priced at $75.64, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas AIH's P/E ratio is -2.78. In terms of profitability, USPH's ROE is +0.06%, compared to AIH's ROE of +1.16%. Regarding short-term risk, USPH is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check AIH's competition here
USPH vs CANO Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, USPH is priced at $75.64, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas CANO's P/E ratio is -0.01. In terms of profitability, USPH's ROE is +0.06%, compared to CANO's ROE of -1.49%. Regarding short-term risk, USPH is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CANO's competition here
USPH vs FTRP Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, USPH is priced at $75.64, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas FTRP's P/E ratio is -1.22. In terms of profitability, USPH's ROE is +0.06%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, USPH is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check FTRP's competition here
USPH vs GBNH Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, USPH is priced at $75.64, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas GBNH's P/E ratio is -0.06. In terms of profitability, USPH's ROE is +0.06%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, USPH is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check GBNH's competition here
USPH vs RHE Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, USPH is priced at $75.64, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas RHE's P/E ratio is -1.79. In terms of profitability, USPH's ROE is +0.06%, compared to RHE's ROE of +1.52%. Regarding short-term risk, USPH is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check RHE's competition here
USPH vs MNDR Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, MNDR has a market cap of 4.5M. Regarding current trading prices, USPH is priced at $75.64, while MNDR trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas MNDR's P/E ratio is -0.15. In terms of profitability, USPH's ROE is +0.06%, compared to MNDR's ROE of -5.70%. Regarding short-term risk, USPH is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check MNDR's competition here
USPH vs ATIP Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, USPH is priced at $75.64, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas ATIP's P/E ratio is -0.03. In terms of profitability, USPH's ROE is +0.06%, compared to ATIP's ROE of +1.77%. Regarding short-term risk, USPH is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check ATIP's competition here
USPH vs NIVFW Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, NIVFW has a market cap of 2.7M. Regarding current trading prices, USPH is priced at $75.64, while NIVFW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas NIVFW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.06%, compared to NIVFW's ROE of -0.39%. Regarding short-term risk, USPH is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check NIVFW's competition here
USPH vs IMACW Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, USPH is priced at $75.64, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas IMACW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.06%, compared to IMACW's ROE of +2.05%. Regarding short-term risk, USPH is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check IMACW's competition here
USPH vs SYRA Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, SYRA has a market cap of 1.2M. Regarding current trading prices, USPH is priced at $75.64, while SYRA trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas SYRA's P/E ratio is -0.31. In terms of profitability, USPH's ROE is +0.06%, compared to SYRA's ROE of -1.04%. Regarding short-term risk, USPH is more volatile compared to SYRA. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check SYRA's competition here
USPH vs CCM Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, CCM has a market cap of 846.4K. Regarding current trading prices, USPH is priced at $75.64, while CCM trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas CCM's P/E ratio is -0.53. In terms of profitability, USPH's ROE is +0.06%, compared to CCM's ROE of +0.08%. Regarding short-term risk, USPH is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check CCM's competition here
USPH vs RHE-PA Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, RHE-PA has a market cap of 674.5K. Regarding current trading prices, USPH is priced at $75.64, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, USPH's ROE is +0.06%, compared to RHE-PA's ROE of +1.52%. Regarding short-term risk, USPH is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check RHE-PA's competition here
USPH vs BACK Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, BACK has a market cap of 227.1K. Regarding current trading prices, USPH is priced at $75.64, while BACK trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas BACK's P/E ratio is -0.01. In terms of profitability, USPH's ROE is +0.06%, compared to BACK's ROE of +2.05%. Regarding short-term risk, USPH is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check BACK's competition here
USPH vs IONM Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, IONM has a market cap of 176.4K. Regarding current trading prices, USPH is priced at $75.64, while IONM trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas IONM's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.06%, compared to IONM's ROE of +0.75%. Regarding short-term risk, USPH is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check IONM's competition here
USPH vs NVOS Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, NVOS has a market cap of 65.1K. Regarding current trading prices, USPH is priced at $75.64, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas NVOS's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.06%, compared to NVOS's ROE of -1.20%. Regarding short-term risk, USPH is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check NVOS's competition here
USPH vs PIIIW Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, PIIIW has a market cap of 32.7K. Regarding current trading prices, USPH is priced at $75.64, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, USPH's ROE is +0.06%, compared to PIIIW's ROE of -1.29%. Regarding short-term risk, USPH is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check PIIIW's competition here
USPH vs DVCR Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, USPH is priced at $75.64, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas DVCR's P/E ratio is 28.34. In terms of profitability, USPH's ROE is +0.06%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, USPH is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check DVCR's competition here
USPH vs TVTY Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, USPH is priced at $75.64, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas TVTY's P/E ratio is 19.06. In terms of profitability, USPH's ROE is +0.06%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, USPH is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check TVTY's competition here
USPH vs TLMDW Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, USPH is priced at $75.64, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas TLMDW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.06%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, USPH is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check TLMDW's competition here
USPH vs SLHGP Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, USPH is priced at $75.64, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, USPH's ROE is +0.06%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, USPH is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check SLHGP's competition here
USPH vs SLHG Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, USPH is priced at $75.64, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas SLHG's P/E ratio is -1.48. In terms of profitability, USPH's ROE is +0.06%, compared to SLHG's ROE of N/A. Regarding short-term risk, USPH is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check SLHG's competition here
USPH vs DCGOW Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, USPH is priced at $75.64, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas DCGOW's P/E ratio is N/A. In terms of profitability, USPH's ROE is +0.06%, compared to DCGOW's ROE of -0.00%. Regarding short-term risk, USPH is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for USPH.Check DCGOW's competition here
USPH vs NFH Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, NFH has a market cap of 0. Regarding current trading prices, USPH is priced at $75.64, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas NFH's P/E ratio is -19.75. In terms of profitability, USPH's ROE is +0.06%, compared to NFH's ROE of -0.06%. Regarding short-term risk, USPH is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check NFH's competition here
USPH vs HNGR Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, USPH is priced at $75.64, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas HNGR's P/E ratio is 19.71. In terms of profitability, USPH's ROE is +0.06%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, USPH is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check HNGR's competition here
USPH vs TLMD Comparison July 2025
USPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, USPH stands at 1.2B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, USPH is priced at $75.64, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
USPH currently has a P/E ratio of 34.74, whereas TLMD's P/E ratio is -1.60. In terms of profitability, USPH's ROE is +0.06%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, USPH is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for USPH.Check TLMD's competition here